T2	Exp 65 85	the unique phenotype
T3	Exp 414 432	their contribution
T4	Exp 295 322	the functional significance
T5	Exp 360 390	the viral long terminal repeat
T6	Exp 436 456	the unique phenotype
T7	Exp 256 266	This study
T8	Exp 553 557	that
T9	Exp 639 673	the basal transcriptional activity
T10	Exp 677 684	the LTR
T11	Exp 880 885	which
T12	Exp 798 808	These LTRs
T13	Exp 975 985	these LTRs
T14	Exp 1403 1405	it
T15	Exp 1273 1277	that
T16	Exp 1195 1202	the use
T17	Exp 1331 1361	the 22-bp sequence duplication
T18	Exp 1366 1378	the NF kappa
T19	Exp 1278 1307	these transcriptional effects
T20	Exp 1440 1444	that
T21	Exp 1470 1477	the LTR
T22	Exp 1494 1501	The LTR
T23	Exp 1554 1566	the kinetics
T24	Exp 1731 1735	that
T25	Exp 1694 1704	the extent
T26	Exp 1620 1628	this LTR
T27	Exp 1951 1953	it
T28	Exp 1853 1857	that
T29	Exp 1838 1852	the hypothesis
T30	Exp 1989 2004	the acute phase
T31	Exp 1804 1817	These studies
R9	Coref Anaphora:T3 Antecedent:T32
R10	Coref Anaphora:T8 Antecedent:T33
R11	Coref Anaphora:T11 Antecedent:T34
R12	Coref Anaphora:T14 Antecedent:T18
R13	Coref Anaphora:T20 Antecedent:T35
R14	Coref Anaphora:T24 Antecedent:T36
R15	Coref Anaphora:T28 Antecedent:T29
R16	Coref Anaphora:T27 Antecedent:T37
T1	Protein 1075 1102	tumor necrosis factor alpha
T32	Exp 337 356	described mutations
T33	Exp 522 552	luciferase reporter constructs
T34	Exp 867 878	SIVsmmPBj14
T35	Exp 1416 1439	infectious virus stocks
T36	Exp 1708 1730	cellular proliferation
T37	Exp 1879 1890	SIVsmmPBj14
